<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987909</url>
  </required_header>
  <id_info>
    <org_study_id>US-C-01</org_study_id>
    <secondary_id>Cetero Research - P2CR09001</secondary_id>
    <secondary_id>Health Canada - 9427-A1556-24C</secondary_id>
    <nct_id>NCT00987909</nct_id>
  </id_info>
  <brief_title>Exposure Chamber Trial With Cat Immunotherapy</brief_title>
  <official_title>A Phase II Trial Assessing the Tolerability and Pharmacodynamic Effect of US SLIT Cat Hair in Subject With Cat Allergy and Investigating Efficacy Variables in an Environmental Exposure Chamber Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cetero Research, San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to investigate if any of three different doses of cat hair
      immunotherapy is safe for treatment of cat allergic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>During 16 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rhinoconjunctivitis symptom score</measure>
    <time_frame>After 0, 8, and 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall rhinoconjunctivitis symptom score</measure>
    <time_frame>After 0, 8, and 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acoustic Rhinometry</measure>
    <time_frame>After 0, 8, and 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Environmental Exposure Chamber Quality of Life</measure>
    <time_frame>After 0, 8, and 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum immunology</measure>
    <time_frame>After 0, 8, and 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal secretion immunology</measure>
    <time_frame>After 0 and 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety lab testing (clinical chemistry, haematology, urinalysis)</measure>
    <time_frame>After 0 and 16 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cat Allergy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution resembling the active solutions, but without allergen extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cat hair allergen extract, dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cat hair allergen extract, dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cat hair allergen extract, dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Specific allergen immunotherapy (placebo)</intervention_name>
    <description>Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Specific allergen immunotherapy</intervention_name>
    <description>Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.</description>
    <arm_group_label>Cat hair allergen extract, dose group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Specific allergen immunotherapy</intervention_name>
    <description>Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks</description>
    <arm_group_label>Cat hair allergen extract, dose group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Specific allergen immunotherapy</intervention_name>
    <description>Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks</description>
    <arm_group_label>Cat hair allergen extract, dose group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A history of rhinoconjunctivitis on exposure to cats

          -  Positive Skin Prick Test response (wheal diameter at least 3 mm larger than the
             negative control

          -  Positive specific IgE against Fel d1 (at least IgE Class 2)

          -  Minimum qualifying rhinoconjunctivitis symptom score during EEC exposure at Visit 2

        Exclusion Criteria:

          -  Uncontrolled asthma within the past 12 months, or asthma requiring regular use of
             inhaled corticosteroids

          -  FEV1 less than 80% of predicted

          -  Subjects who suffer from significant seasonal allergic rhinoconjunctivitis, and cannot
             complete the clinical trial outside the local pollen season, or who have significant
             allergy to other allergens (e.g. other animals or house dust mites) that cannot be
             avoided during the trial period

          -  Subjects who cannot tolerate baseline challenge in the Environmental Exposure Chamber

          -  History of anaphylaxis with cardio/respiratory symptoms

          -  A medical history of severe drug or food allergy with symptoms such as difficulty
             breathing, swelling of the face or a feeling of severe dizziness or increased heart
             rate

          -  Chronic urticaria

          -  History of severe cardiac disease

          -  Treatment with immunosuppressives, anti-IgE monoclonal antibodies, tricyclic
             antidepressants or MAOIs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepen Patel, MD, CCFP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <last_update_submitted>August 17, 2010</last_update_submitted>
  <last_update_submitted_qc>August 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Senior Director Global Clinical Development</name_title>
    <organization>ALK-Abelló A/S</organization>
  </responsible_party>
  <keyword>Cat</keyword>
  <keyword>Allergy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Sublingual</keyword>
  <keyword>Exposure chamber</keyword>
  <keyword>Safety</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

